Remote monitoring in rheumatoid arthritis
| ISRCTN | ISRCTN25879022 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN25879022 |
| IRAS number | 313072 |
| Secondary identifying numbers | IRAS 313072 |
- Submission date
- 04/05/2022
- Registration date
- 05/05/2022
- Last edited
- 14/06/2024
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Musculoskeletal Diseases
Plain English summary of protocol
Background and study aims
Rheumatoid arthritis is a common disease affecting 1 in 100 UK adults, causing joint pain, stiffness and fatigue. Patients with rheumatoid arthritis need close monitoring of their arthritis activity to work out the most effective dose of their arthritis drugs. At the moment, this monitoring is done at clinic visits, meaning that patients have to regularly attend hospital. If it were possible for patients to be monitored remotely, this would avoid many trips to hospital and free up clinic appointments for those patients most in need. In this small study, we aim to assess the feasibility of remote monitoring in patients with active rheumatoid arthritis who are starting an arthritis drug.
Who can participate?
Patients with a diagnosis of rheumatoid arthritis, who are starting a new rheumatoid arthritis drug treatment.
What does the study involve?
We will invite 20 patients to take part and will be followed for three months. Patients will complete self-assessments of their arthritis activity using online questionnaires, and their physical activity and heart rate will be measured using small wearable monitors. Patients will also attend for monthly face-to-face visits with a nurse to assess their arthritis activity using standard measurements used in current clinical practice. We will compare remote measurements of arthritis activity with standard face-to-face assessments to assess their accuracy and reliability. Also, information from activity and heart rate monitors will be analysed to look for patterns that may identify when patients have active arthritis. Finally, patients will provide feedback on their experience of remote monitoring, and any aspects for future improvement.
What are the possible benefits and risks of participating?
There will be no direct benefit to participants for participating in this study. They will be making a valuable contribution to our understanding about the feasibility of remote monitoring in rheumatoid arthritis. In the future this may lead to new tools to check people’s arthritis between hospital visits, improving the quality and safety of care that we can provide to our patients. There are no obvious disadvantages or risks to taking part in the study. The monitors and smartphone that participants will be required to wear and use are non-invasive and have no associated risks. Sometimes blood tests can cause some minor bruising.
Where is the study run from?
Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust (UK)
When is the study starting and how long is it expected to run for?
December 2021 to September 2023
Who is funding the study?
The National Institute for Health and Care Research Newcastle Biomedical Research Centre (UK)
Who is the main contact?
Dr Kenneth Baker, kenneth.baker@ncl.ac.uk
Contact information
Principal Investigator
Translational and Clinical Research Institute
3rd Floor, William Leech Building
Medical School, Newcastle University
Newcastle upon Tyne
NE2 4HH
United Kingdom
 ORCID ID |
0000-0002-6735-2911 |
|---|---|
| Phone | +44 1912085337 |
| kenneth.baker@ncl.ac.uk |
Public
Translational and Clinical Research Institute
3rd Floor, William Leech Building
Medical School, Newcastle University
Newacstle upon Tyne
NE2 4HH
United Kingdom
| Phone | +44 1912085337 |
|---|---|
| kenneth.baker@ncl.ac.uk |
Scientific
Translational and Clinical Research Institute
3rd Floor, William Leech Building
Medical School, Newcastle University
Newcastle upon Tyne
NE2 4HH
United Kingdom
| Phone | +44 1912085337 |
|---|---|
| kenneth.baker@ncl.ac.uk |
Study information
| Study design | Single centre observational longitudinal cohort study |
|---|---|
| Primary study design | Observational |
| Secondary study design | Longitudinal study |
| Study setting(s) | Hospital |
| Study type | Other |
| Participant information sheet | Not available in web format, please use contact details to request a participant information sheet |
| Scientific title | Remote monitoring of disease and physical activity in rheumatoid arthritis: a pilot study |
| Study objectives | To demonstrate the feasibility of remote disease activity monitoring in participants with rheumatoid arthritis, to support a future clinical efficacy trial. |
| Ethics approval(s) | Approved 23/05/2022, North of Scotland Research Ethics Committee (Summerfield House, 2 Eday Road, Aberdeen, AB15 6RE, UK; +44 (0)1224558458; gram.nosres@nhs.scot), ref: 22/NS/0072 |
| Health condition(s) or problem(s) studied | Rheumatoid arthritis |
| Intervention | In this pilot study, we propose to recruit 20 participants with rheumatoid arthritis (RA) with active disease who are newly starting a disease modifying antirheumatic drug (DMARD). Participants will be followed for 3 months, with monthly face-to-face visits to measure the disease activity in 28 joints (DAS28) score. Throughout the study, participants will complete weekly patient-reported outcome measures (PROMs) in the form of the simple 5-question RA Disease Activity Index 5 (RADAI-5), captured electronically using the British Society for Rheumatology ePROMs online portal, with weekly email reminders to support participant uptake. In addition, at each monthly visit participants will be provided with activity trackers (lower back and wrist – Axivity AX6) and a combined activity and cardiorespiratory monitor (VitalPatch) to be worn for 7 days. Additional PROMs including FACIT-F and MFS (fatigue), HAQ-DI (physical function), PHQ-2 (anxiety/depression) and EQ-5D-5L (general health) will be captured at the monthly visits, in order to collect information necessary for interpretation of the activity monitor data. |
| Intervention type | Not Specified |
| Primary outcome measure | 1. Arthritis activity measured using the disease activity score in 28 joints (DAS28) score at baseline, week 4, week 8 and week 12. 2. Arthritis activity measured using the rheumatoid arthritis disease activity index 5 (RADAI-5) at baseline, week 4, week 8 and week 12 |
| Secondary outcome measures | 1. Physical activity measured by Axivity AX6 devices at baseline, week 4, week 8 and week 12 2. Cardiorespiratory activity measured by VitalPatch devices at baseline, week 4, week 8 and week 12 3. Fatigue measured by the FACIT-F questionnaire at baseline, week 4, week 8 and week 12 4. Fatigue measured by the MFS questionnaire at baseline, week 4, week 8 and week 12 5. Physical function measured by the HAQ-DI questionnaire at baseline, week 4, week 8 and week 12 6. Anxiety and depression measured by the PHQ-2 questionnaire at baseline, week 4, week 8 and week 12 7. General health measured by the EQ-5D-5L questionnaire at baseline, week 4, week 8 and week 12 |
| Overall study start date | 17/12/2021 |
| Completion date | 30/09/2023 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 20 |
| Total final enrolment | 13 |
| Key inclusion criteria | 1. Diagnosis of rheumatoid arthritis according to the 1987 American College of Rheumatology (ACR) or 2010 ACR/European Alliance of Associations for Rheumatology (EULAR) classification criteria applied at any time since diagnosis. 2. Participant about to commence (i.e. planned within next 4 weeks), or recently commenced (i.e. within past 8 weeks), a new disease-modifying anti-rheumatic drug (i.e. conventional synthetic DMARD, Janus-kinase inhibitor or biologic therapy) 3. Able to walk at least four metres independently without walking aids 4. Participant willing to commit to complete remote monitoring measurements and wear monitoring devices |
| Key exclusion criteria | 1. Unable to read or communicate in English 2. Current participation within an interventional clinical trial (participation in another observational trial is permitted) 3. Inability to provide informed consent 4. Age less than 18 years 5. Current diagnosis of a movement disorder 6. Current pregnancy |
| Date of first enrolment | 01/06/2022 |
| Date of final enrolment | 30/06/2023 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Freeman Road
High Heaton
Newcastle upon Tyne
NE7 7DN
United Kingdom
Sponsor information
Hospital/treatment centre
Newcastle Joint Research Office
Level 1, Regent Point
Regent Farm Road
Gosforth
Newcastle upon Tyne
NE3 3HD
England
United Kingdom
| Phone | +44 191 233 6161 |
|---|---|
| nuth.genericqueries@nhs.net | |
| Website | http://www.newcastle-hospitals.org.uk/ |
"ROR" |
https://ror.org/05p40t847 |
Funders
Funder type
Government
Private sector organisation / Research institutes and centers
- Alternative name(s)
- Newcastle Biomedical Research Centre, Newcastle NIHR Biomedical Research Centre
- Location
- United Kingdom
Results and Publications
| Intention to publish date | 30/06/2025 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| Publication and dissemination plan | Planned publication in a high-impact peer-reviewed journal |
| IPD sharing plan | The data-sharing plans for the current study are unknown and will be made available at a later date |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| HRA research summary | 28/06/2023 | No | No |
Editorial Notes
14/06/2024: The intention to publish date was changed from 30/06/2024 to 30/06/2025.
12/09/2023: The following changes were made:
1. The intention to publish date was changed from 30/09/2024 to 30/06/2024.
2. The total final enrolment number was added.
19/01/2023: The following changes were made:
1. The recruitment end date was changed from 31/01/2023 to 30/06/2023.
2. The overall trial end date was changed from 30/04/2023 to 30/09/2023.
3. The intention to publish date was changed from 30/04/2024 to 30/09/2024.
09/06/2022: The ethics approval has been added.
05/05/2022: Trial's existence confirmed by The Newcastle upon Tyne Hospitals NHS Foundation Trust
